10 Micro and Small-Cap Firms Drive Year-to-Date Gains

7. Invivyd Inc. (NASDAQ:IVVD)

Invivyd saw its year-to-date share prices rally by 263 percent to end Friday’s trading at $1.61 versus the 44 cents registered last December 31, as investor sentiment continues to be fueled by positive developments from its clinical trials.

On February 5, IVVD—a pharmaceutical company with a $192.58-million market capitalization—registered its highest price for the year at $2.11, representing a 376-percent surge from December 31’s price, after the company announced that its pipeline candidate, VYD2311, demonstrated promising neutralizing activity against the dominant SARS-CoV-2 variant XEC.

The result further supported the effectiveness of IVVD’s monoclonal antibodies, including Pemgarda (pemivibart).

IVVD officially submitted its latest findings to the Food and Drug Administration (FDA), and is expected to update the Pemgarda fact sheet for healthcare providers soon.